Mar 13, 2023 / 02:00PM GMT
Steve Lichtman - Oppenheimer & Co. - Analyst
Hi, everyone. I'm Steve Lichtman, medical devices analyst at Oppenheimer, and welcome to the 33rd Annual Oppenheimer Healthcare Conference. Very happy to have up with us next, RxSight. With us today from RxSight are CEO, Ron Kurtz; and CFO, Shelley Thunen.
We will have a presentation from Ron and Shelley, and then we'll have some time for Q&A. So if you do have a question, please just key it in into the chat, and I will get it over to management. But with that, I'm happy to turn the podium over to Ron. Thanks.
Ron Kurtz - RxSight, Inc. - President, CEO, & Director
Thank you, Steve, and it's a pleasure to be here this morning. These are our forward-looking statements. So just to begin, RxSight is focused on the growing premium cataract surgery market, which is the most profitable segment of the highest-volume surgical procedure in ophthalmology.
Our strategy is based on delivering both better medicine for patients and better business results for doctors and practices, an approach that our
Rxsight Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
Mar 13, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers